Biogen's Alzheimer's Drug Success Pops Stocks Across the Industry
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.
For the 55 million people around the world who suffer from Alzheimer's and related dementias -- not to mention their loved ones -- Biogen's successful drug trial is a ray of hope.
Shares in Biogen and its partner Eisai catapulted higher on Wednesday after the duo announced they would apply for regulatory approval for a new Alzheimer's drug following the success of a late-stage clinical trial. The results are a landmark achievement that injects new hope into a line of scientific thinking and research that's been met by nothing but disappointment.
Source Fool.com
